| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/18/2002 | US20020045662 Stable gabapentin having pH within a controlled range |
| 04/18/2002 | US20020045660 For enhancing neurological development of preterm infants; arachidonic acid and/or docosahexaenoic acid; enhances visual, language and motor development without anthropomethric growth inhibition |
| 04/18/2002 | US20020045659 Use, in cosmetic preparations, of prostaglandin EP-3 receptor agonists to attenuate, reduce or stop the growth of head hair and other hairs |
| 04/18/2002 | US20020045656 NMDA receptor NR2B subunit antagonist and a neutrophil inhibiting factor; therapies that reduce or prevent neuronal dysfunction and death after ischemic, hypoxic or traumatic CNS insult |
| 04/18/2002 | US20020045655 Oxime amides and hydrazone amides having fungicidal activity |
| 04/18/2002 | US20020045654 Sulfonylbenzene compounds as anti-inflammatory/analgesic agents |
| 04/18/2002 | US20020045652 Prophylactic or therapeutic drug for renal diseases |
| 04/18/2002 | US20020045651 Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones |
| 04/18/2002 | US20020045650 Substituted indole proteolytic enzyme inhibitors as cancer treating agents |
| 04/18/2002 | US20020045649 Treatment of diabetes with thiazolidinedione and sulphonylurea |
| 04/18/2002 | US20020045648 Therapeutic compositions comprising excess enantiomer |
| 04/18/2002 | US20020045647 N-linked urea or carbamate of heterocyclic thioester hair growth compositons and uses |
| 04/18/2002 | US20020045646 Pharmaceutical preparations comprising substituted benzimidazole proton pump inhibitors with fast acting buffer; gastric acid stability for enteral administration |
| 04/18/2002 | US20020045645 Lactone integrin antagonists |
| 04/18/2002 | US20020045644 2-phenylpyran-4-one derivatives |
| 04/18/2002 | US20020045643 Isoindolines, method of use, and pharmaceutical compositions |
| 04/18/2002 | US20020045642 Antiinflammatory, -arthritic and -emetic agents; central nervous system disorders; Parkinson's disease; antidepressants; psychological disorders; anxiolytic agents; antagonists of substance P receptors |
| 04/18/2002 | US20020045641 Multiple heteroatom containing heterocyclic ring compounds substituted with carboxylic acids and isosteres thereof |
| 04/18/2002 | US20020045640 Anellated dihydropyridines for the treatment of chronic pain |
| 04/18/2002 | US20020045639 Combination of huperzine and nicotinic compounds as a neuroprotective agent |
| 04/18/2002 | US20020045638 Method of treating estrogen receptor positive carcinoma |
| 04/18/2002 | US20020045637 Novel 20,21-dinor-eburnamenine |
| 04/18/2002 | US20020045636 Administering a drug composition comprising an opioidergic agent (e.g. an opiate antagonist, an opiate having mu-agonist activity, or a combination) and an insulin secretagogue |
| 04/18/2002 | US20020045635 Novel mGluR antagonists and a method for their synthesis |
| 04/18/2002 | US20020045633 Use of moxonidine for postmyocardial infarction treatment |
| 04/18/2002 | US20020045632 Synergistic antitumor mixture of tegafur, uracil and folinic acid to potentiate coadministered oxaliplatin; colorectal cancer |
| 04/18/2002 | US20020045630 Antiproliferative, -carcinogenic, -tumor and -diabetic agents; binding to or modulating the human kinase insert-domain-containing receptor (KDR) or the murine fetal liver kinase 1 (FLK-1) receptor; vasculogenesis; angiogenesis |
| 04/18/2002 | US20020045629 Sleep, eating and brain disorders, wakefulness promoters; Parkinson's disease, antiischemic agents, stroke, chronic fatigue syndrome; antidepressants; schizophrenia, nervous system disorders; multiple sclerosis, cognition activators |
| 04/18/2002 | US20020045625 Oxazolidinone chemotherapeutic agents |
| 04/18/2002 | US20020045624 Treatment of central nervous system (CNS) dysfunctions, neurodegenerative diseases and neurotoxic injury following hypoxia, anoxia or ischemia of stroke, cardiac arrest or perinatal asphyxia; antipsychotic and -convulsant agents |
| 04/18/2002 | US20020045623 Stable; potent; penetrates cell membranes; effectively hinders cellular apoptosis; Antiinflammatory agents, Ischemic agents, cancer, autoimmune diseases and nervous system disorders. |
| 04/18/2002 | US20020045622 Growth hormone secretagogues |
| 04/18/2002 | US20020045621 A mobile ionophore composition effective to modulate APP catabolism without substantially altering the viability of APP-containing cells; inhibits amyloid deposition; Alzheimer's disease; nontoxic |
| 04/18/2002 | US20020045619 4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents |
| 04/18/2002 | US20020045618 Heteroaryl diazacycloalkanes, their preparation and use |
| 04/18/2002 | US20020045617 Act preferentially on M4 receptors; side effect reduction; used to treat nervous system disorders, psychological disorders and as an analgesic; Alzheimer's disease; Cognition activators. |
| 04/18/2002 | US20020045616 Lactam inhibitors of FXa and method |
| 04/18/2002 | US20020045615 Benzothiazole derivatives with activity as adenosine receptor ligands |
| 04/18/2002 | US20020045614 1-(4-(((4-Amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino) methyl)-4-phenyl-piperidin-1-yl)-1-cyclopropyl-methanone; treating disease states ameliorated by blockade of alpha-1 adrenoceptors; sleep/psychological disorders |
| 04/18/2002 | US20020045613 1-aroyl-piperidinyl benzamidines |
| 04/18/2002 | US20020045612 Endocrine modulation with positive modulators of AMPA type glutamate receptors |
| 04/18/2002 | US20020045611 Pharmaceutical compositions comprising metal complexes |
| 04/18/2002 | US20020045610 Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis |
| 04/18/2002 | US20020045608 Drug addiction, drug dependence |
| 04/18/2002 | US20020045607 Cholesterol and hedgehog signaling |
| 04/18/2002 | US20020045605 Method of treating colonic adenomas |
| 04/18/2002 | US20020045604 Formulations for treating or preventing mucositis |
| 04/18/2002 | US20020045603 Method of inhibiting membrane-type matrix metalloproteinase |
| 04/18/2002 | US20020045602 7-substituted fused ring tetracycline compounds |
| 04/18/2002 | US20020045599 Crystalline adefovir dipivoxil |
| 04/18/2002 | US20020045597 N-acylated-2-glucosamine derivatives for treating osteoarthritis/inflammatory arthritis, and enhancing cartilage formulation, chondrocyte cell proliferation and glycosaminoglycan production |
| 04/18/2002 | US20020045596 Aging resistance; oxidation resistance |
| 04/18/2002 | US20020045595 N6 heterocyclic 8-modified adenosine derivatives |
| 04/18/2002 | US20020045586 Mono-and disaccharides for the treatment of nitric oxide related disorders |
| 04/18/2002 | US20020045585 Cytoskeletal active agents for glaucoma therapy |
| 04/18/2002 | US20020045584 Acyclic isoprenoid ether derivatives as chemotherapeutics |
| 04/18/2002 | US20020045580 Compositions for raising uric acid levels and methods of using same |
| 04/18/2002 | US20020045579 Modulation of inflammation related to columnar epithelia |
| 04/18/2002 | US20020045577 Human schizophrenia gene |
| 04/18/2002 | US20020045573 Dithiocarbamates linked to the surface of a non-immunogenic, non-targeting macromolecule other than an antibody (e.g., albumin protein); treating cerebral stroke and other ischemia/reperfusion injury |
| 04/18/2002 | US20020045572 Method of treating the syndrome of type 2 diabetes in humans |
| 04/18/2002 | US20020045570 Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases |
| 04/18/2002 | US20020045566 Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
| 04/18/2002 | US20020045565 Administering to the patient an alpha-2 adrenoreceptor agonist for the treatment or prevention of emesis |
| 04/18/2002 | US20020045222 Compositions and methods for saccharide synthesis |
| 04/18/2002 | US20020045213 IL-17 receptor like molecules and uses thereof |
| 04/18/2002 | US20020045206 Contacting the cells with a trophic amount of a ptc therapeutic for promoting survival of substantia nigra neuronal cells |
| 04/18/2002 | US20020045203 Method for detecting active ingredients of medical value |
| 04/18/2002 | US20020045199 Preventing, inhibiting or enhancing binding between at least one type of pilus subunit and at least one type of periplasmic molecular chaperone in the pilus-forming bacteria for therapy or prophylaxis of diseases |
| 04/18/2002 | US20020044992 Calcium compound and an acidulant; pH of the composition is from 3.5 to 4.5; having reduced tooth erosion characteristics, especially acid beverages such as fruit juice |
| 04/18/2002 | US20020044991 At least two cores of a multicore structure have a different chemical composition; used to produce food supplements, and as additive to foods, animal feeds, pharmaceutical and cosmetic preparations. |
| 04/18/2002 | US20020044981 Mixture of polyunsaturated fatty acids containing linoleic, gamma-linolenic, alpha-linolenic, and stearidonic acid; antilipemic agent, antioxidant and/or antidiabetic agent. |
| 04/18/2002 | US20020044980 Nutritional suplement based on blackcurrent seed oil |
| 04/18/2002 | US20020044978 Allicin-containing garlic extracts |
| 04/18/2002 | US20020044973 Microparticles and their use in cancer treatment |
| 04/18/2002 | US20020044967 Sustained release preparations |
| 04/18/2002 | US20020044966 Pharmaceutical formulations containing an opioid and an alpha-agonist |
| 04/18/2002 | US20020044965 Side effect profile reduction |
| 04/18/2002 | US20020044961 Nutritional formulations |
| 04/18/2002 | US20020044958 Disaccharide protector; frozen; preserved for longer than one year; shows excellent restoration ability in water |
| 04/18/2002 | US20020044943 Mucin MUC-1; including organ transplant rejection or graft versus host disease |
| 04/18/2002 | US20020044937 Where the protein binds to T-cell cell surface protein, and that complex with nucleic acids, for transporting nucleic acids into human or animal cells which express the T-cell surface protein; antisense therapy, HIV therapy |
| 04/18/2002 | US20020044920 Administration of a therapeutically-effective amount of a TNF antagonist, such as etanercept or infliximab, or a therapeutically-effective amount of a pyrimidine synthesis inhibitor, such as leflunomide |
| 04/18/2002 | US20020044919 Combinations and methods for treating neoplasms |
| 04/18/2002 | US20020044914 Inhibitors of melanocyte tyrosinase as topical skin lighteners |
| 04/18/2002 | US20020044909 Cyanine dye bioconjugates with bioactive molecules for diagnosis and therapy, particularly for visualization and detection of tumors |
| 04/18/2002 | US20020044899 Controlled, super-fine grinding so particles react completely during leaching; extraction of copper from copper sulfide ores and concentrates |
| 04/18/2002 | US20020043207 Oxidizing 2-((diphenylmethyl)thio)acetamide with hydrogen peroxide in mixture of mineral acid with alcohol or phase transfer catalyst, precipitating solid, and separating |
| 04/18/2002 | DE10140028A1 Verfahren zur Herstellung von Citalopram A process for the preparation of citalopram |
| 04/18/2002 | DE10122447A1 Biphenylcarboxamide Biphenylcarboxamides |
| 04/18/2002 | DE10060550C1 Transdermal therapeutic system for administration of oxybutynin, especially for treatment of bladder dysfunction, having two-phase matrix layer of active agent-containing droplets dispersed in adhesive |
| 04/18/2002 | DE10050995A1 New benzylic acid azabicyclooctane ester quaternary salts useful as anticholinergic agents, especially in treatment of asthma and chronic obstructive pulmonary disease |
| 04/18/2002 | DE10050994A1 New diphenylalkanoic acid azabicyclooctane ester quaternary salts useful as anticholinergic agents, especially in treatment of asthma and chronic obstructive pulmonary disease |
| 04/18/2002 | DE10050663A1 Use of amino-substituted imidazo(1,2-a)pyridine, imidazo(1,2-a)pyrimidine and imidazo(1,2-a)pyrazine derivatives as NO synthase inhibitors, e.g. in treatment of migraine and neurodegenerative diseases |
| 04/18/2002 | DE10050662A1 New substituted dihydropyrido-pyrimidine derivatives, useful for treating e.g. pain, urinary incontinence and tinnitus |
| 04/18/2002 | DE10050661A1 New substituted 3,4-dihydro-pyrimido(1,2-a)pyrimidine and 3,4-dihydro-pyrazino(1,2-a)pyrimidine derivatives useful for the treatment of pain, urinary incontinence, pruritis, tinnitus and diarrhea |
| 04/18/2002 | DE10049736A1 17alpha-Fluoralkylsteroide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen 17alpha-Fluoroalkyl steroids, processes for their preparation and pharmaceutical compositions containing them |
| 04/18/2002 | DE10047319A1 Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen, welche durch die Hemmung der Aktivierung des nukleären Transkriptionsfaktors AP-1 therapeutisch beeinflußt werden können Use of R-arylpropionic acids for producing medicaments for treating diseases that can be therapeutically affected by the inhibition of activation of the nuclear transcription factor AP-1 |
| 04/18/2002 | DE10047116A1 DELTA·1·-Pyrroline DELTA · 1 · -Pyrrolines |
| 04/18/2002 | CA2765409A1 Hydroxamic acid compounds comprising a sulfonamide linkage as hdac inhibitors |